Critical Pharmaceuticals Door

Latest News

CP046 Nasal PTH

nasal devices

CP046 nasal teriparatide (parathyroid hormone PTH 1-34) is being developed in collaboration with the University of Nottingham.

Read more

CP024 Nasal hGH

measuring height

CP024 has completed two Phase 1 clinical trials where our intranasal growth hormone has shown comparable activity to injection.

Read more

Dr Gareth King, CEO Critical Pharmaceuticals
"The allowance of a US patent further strengthens the data package on our CP024 nasal growth hormone product that has demonstrated strong biological activity in Phase I clinical trials. It will provide important protection to future license partners for the continued development and commercialisation of CP024 and CP046 intranasal teriparatide products."